This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: ODYSSEY

Innovations in cardiorenal medicine

February 2017 Br J Cardiol 2017;24:13 Online First

Innovations in cardiorenal medicine

Richard Crawley

Abstract

Targeting uric acid Dr Richard Crawley (Portsmouth Hospitals NHS Trust) The conference’s keynote lecture, delivered by Professor Austin Stack (University Hospital, Limerick, Ireland), homed in on the idea that serum uric acid directly contributes to increased cardiovascular disease. This was shown in his team’s work published in 2013,1 which used retrospective data to identify a direct correlation between raised serum uric acid concentrations and increased risk of developing cardiovascular disease. This, therefore, begs two questions: Firstly, does uric acid directly cause vascular endothelial damage, contributing to acute renal dysfunct

| Full text

October 2015 Br J Cardiol 2015;22:138–142 Online First

News from the European Society of Cardiology Congress 2015

BJCardio Staff

Abstract

(more…)

| Full text
News from ACC.15

April 2015 Br J Cardiol 2015;22:(2) Online First

News from ACC.15

BJCardio Staff

Abstract

Too much sitting increases coronary artery calcification Sitting for many hours per day is associated with increased coronary artery calcification, a marker of subclinical heart disease, a new study suggests. The study found no association between coronary artery calcification (CAC) and the amount of exercise a person gets, suggesting that too much sitting might have a greater impact than exercise on this particular measure of heart health. The results suggest that exercise may not entirely counteract the negative effects of a mostly sedentary lifestyle on coronary artery calcium. Presenting the study at the ACC meeting, Dr Jacquelyn Kulinski

| Full text
News from the American Heart Association Scientific Sessions 2014

January 2015 Br J Cardiol 2015;22:12–13 Online First

News from the American Heart Association Scientific Sessions 2014

BJCardio Staff

Abstract

IMPROVE-IT: ezetimibe reduces events on top of simvastatin The long-awaited IMPROVE-IT trial has shown that adding ezetimibe to treatment with simvastatin lowers the risk of future cardiovascular events in high-risk patients who had recently suffered an acute coronary syndrome (ACS). The addition of ezetimibe to simvastatin 40 mg was associated with a low-density lipoprotein (LDL) lowering of 15 mg/dL (0.4 mmol/L) which translated into a 6.4% lower risk of cardiovascular events. Lead investigator, Dr Christopher Cannon (Brigham and Women’s Hospital, Boston, USA) said: “The study is the first to show that adding a non-statin drug to a

| Full text

January 2015 Br J Cardiol 2015;22:(1) Online First

Lipid highlights from the American Heart Association

BJCardio Staff

Abstract

IMPROVE-IT: ‘even lower is even better for LDL’ The IMPROVE-IT trial has made history in being the first major clinical outcome study to show a benefit of low-density lipoprotein (LDL)-lowering with a non-statin drug, and is being seen as proof of the ‘lower is better low-density lipoprotein (LDL) hypothesis. In the trial, the addition of ezetimibe to simvastatin for seven years led to a LDL lowering of 15 mg/dL (0.4 mmol/L) which was associated with a relative risk reduction in major cardiovascular events of 6.4% in patients who had recently suffered an acute coronary syndrome (ACS). IMPROVE-IT (Improved Reduction of Outcomes: Vytorin

| Full text

October 2014 Br J Cardiol 2014;21:135–7 Online First

News from the ESC Congress 2014

BJCardio Staff

Abstract

A PARADIGM shift in heart failure therapy A new drug representing a novel therapeutic concept has shown extremely good results in a phase 3 trial in heart failure, generating much excitement. The drug, referred to as an angiotensin receptor-neprilysin inhibitor (ARNI), combines the neprilysin inhibitor sacubitril (AHU377) and the angiotensin receptor blocker (ARB), valsartan. Neprilysin is a neutral endopeptidase involved in the metabolism of a number of vasoactive peptides. Developed by Novartis and known only as LCZ696 at present, the new agent could be on the market next year. In the current study known as PARADIGM-HF, LCZ696 showed signi

| Full text

October 2014 Online First

Lipid highlights from ESC 2014

BJCardio Staff

Abstract

LDL debate All guidelines agree that low-density lipoprotein cholesterol (LDL-C) is the primary lipid target, Irrespective of confusion following the publication of the American College of Cardiology/American Heart Association (ACC/AHA) guideline on cholesterol management,1 which is broadly similar to new NICE (National Institute for Health and Care Excellence) recommendations.2 But questions remain as to what is more relevant for reducing the risk of CVD: how you lower LDL-C or to what extent? This issue was the focus of a hot debate between leading experts, at the symposium: ‘New frontiers in cholesterol management in high CV risk patien

| Full text

October 2014

European Society of Cardiology Congress 2014 Highlights 1

Professor Keith Fox

Abstract

Click to enlarge Our selection of trials, registry data and guideline updates from the 2014 European Society of Cardiology (ESC) Congress. Professor Keith Fox discusses trials in heart failure, coronary artery disease, and arrhythmia. View Kausik Ray interview now View Christopher Cannon interview now This podcast has been made possible by unrestricted educational grants from Bayer Healthcare (Job code L.GB.10.2014.8412; Date of preparation October 2014) and Sanofi/Regeneron (Job code SAGB.CMR.14.10.0599b)

| Full text

October 2014

European Society of Cardiology Congress 2014 Highlights 2

Dr Christopher Cannon

Abstract

Click to enlarge Our selection of trials, registry data and guideline updates from the 2014 European Society of Cardiology (ESC) Congress. Dr Christopher Cannon focuses on the ODYSSEY programme, and adherence issues with PCSK9 monoclonal antibody therapies. View Keith Fox interview now View Kausik Ray interview now This podcast has been made possible by an unrestricted educational grant from Sanofi/Regeneron (Job code SAGB.CMR.14.10.0599a)

| Full text

October 2014

European Society of Cardiology Congress 2014 Highlights 3

Professor Kausik Ray

Abstract

Click to enlarge Our selection of trials, registry data and guideline updates from the 2014 European Society of Cardiology (ESC) Congress. Professor Kausik Ray puts the key studies into clinical perspective, and explains why the extent – not the means – of LDL cholesterol lowering is key in the prevention of CVD. View Keith Fox interview now View Christopher Cannon interview now This podcast has been made possible by an unrestricted educational grant from Sanofi/Regeneron (Job code SAGB.CMR.14.10.0599c)

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now